Analysts from IQVIA found that 340B wholesale acquisition cost sales increased by 17% from 2022 to 2023.

340B Sales Increased 17% to $124B in 2023, Drug Industry Consulting Firm Finds 

The 340B program continued to expand in 2023, exceeding $124 billion in wholesale acquisition cost (WAC) sales—up from $107 billion [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at